EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at
Experience Project.
In this study, treatment with LNA oligonucleotides, developed by Santaris, induced alternative RNA splicing of TNF receptor 2, resulting in a switch from the membrane-bound to a soluble protein form, thus creating a "decoy" receptor, which accumulated in the circulation of treated mice. The generated soluble TNF receptor protein antagonized TNF-alpha, interfered with its inflammatory function, and reduced severity of inflammatory disease in mouse models of hepatitis and arthritis. This is the first report of upregulation of the endogenous, circulating TNF-alpha antagonist by oligonucleotide-induced modulation of splicing.
MDX-1100 is a fully human antibody that targets CXCL10 (also known as
IP-10), a chemokine expressed in association with multiple inflammatory
disease indications such as rheumatoid arthritis, inflammatory bowel
disease and multiple sclerosis.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
Forum FAQ
Search
Usergroups
Profile
Log in to check your private messages
Log in
